Back to results
US 2025/0025504 A1Published application
Treatment of b cell malignancies
AssigneeAdicet Therapeutics, Inc.
InventorsBlake AFTAB, Francesco GALMI, Rose Kamyee LAI, Ori MALLER
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAdicet Therapeutics, Inc.
InventorsBlake AFTAB, Francesco GALMI, Rose Kamyee LAI, Ori MALLER
Estimating the term…
Aspects of the disclosure include methods of effectively treating a relapsed/refractory B cell malignancy in a patient in need thereof who has previously been treated with and ultimately failed at least one, two, or at least three previous therapies. In one example. a method comprises administering to the subject one or more doses comprising a therapeutically effective amount of anti-CD20 CAR γδ T cells that express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20 on a malignant B cell to the subject. Following administration, the subject methods optionally further include monitoring for one or more biomarkers of cell activation and/or therapeutic efficacy that inform the need for and/or type of follow-on treatment regimen.
A method of treating a relapsed/refractory (R/R) B cell malignancy in a patient in need thereof, the method comprising administering to the subject a therapeutically effective amount of anti-CD20 CAR γδ T cells that express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20 on a malignant B cell, thereby treating the patient;
The method of any preceding claim, further comprising administering to the subject a lymphodepletion (LD) regimen prior to administering to the subject a first dose of the therapeutically effective amount of anti-CD20 CAR γδ T cells.
The method of any preceding claim, wherein the anti-CD20 CAR γδ T cells are γδ1 T cells, γδ2 T cells, γδ3 T cells, or γβ4 T cells, preferably wherein the γδ T cells are γδ1 T cells.
A method of treating a relapsed/refractory (R/R) B cell malignancy in a patient in need thereof, the method comprising administering to the subject a lymphodepletion (LD) regimen at least five days prior to administering to the subject a first dose of anti-CD20 CAR γδ T cells, followed by administering to the subject the first dose comprising a therapeutically effective amount of anti-CD20 CAR γδ T cells that express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20 on a malignant B cell, thereby treating the patient;
The method of any of the preceding claims, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
The method of 41, wherein the anti-CD20 γδ T cells further comprise an isolated nucleic acid encoding the CAR.
Dependencies are inferred from the claim text.